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Background The PRAETORIAN trial showed non-inferiority of the subcutaneous 
implantable cardioverter-defibrillator (S-ICD) compared to the transvenous ICD (TV-ICD) 
with regard to inappropriate shocks and complications. In contrast to the TV-ICD, the S-ICD 
cannot provide antitachycardia pacing (ATP) for monomorphic ventricular tachycardia (VT). 
This pre-specified secondary analysis evaluates appropriate therapy and whether ATP reduces 
the number of appropriate shocks. 
Methods: The PRAETORIAN trial was an international, investigator-initiated randomized 
trial, which included patients with an indication for ICD therapy. Patients with prior VTs 
below 170 bpm or refractory recurrent monomorphic VTs were excluded. In 39 centers, 849 
patients were randomized to receive an S-ICD (N=426) or TV-ICD (N=423) and were 
followed for a median of 49.1 months. ICD programming was mandated by protocol. 
Appropriate ICD therapy was defined as therapy for ventricular arrhythmias. Arrhythmias 
were classified as discrete episodes and storm episodes (≥3 episodes within 24 hours). 
Analyses were performed in the modified intention-to-treat population.  
Results: In the S-ICD group, 86/426 patients received appropriate therapy, versus 78/423 
patients in the TV-ICD group, during a median follow-up of 52 months (48-month Kaplan–
Meier estimates 19.4% and 17.5%, P=0.45). In the S-ICD group, 83 patients received at least 
one shock, versus 57 patients in the TV-ICD group (48-month Kaplan–Meier estimates 19.2% 
and 11.5%, P=0.02). Patients in the S-ICD group had a total of 254 shocks, compared to 228 
shocks in the TV-ICD group (P=0.68). First shock efficacy was 93.8% in the S-ICD group 
and 91.6% in the TV-ICD group (P=0.40). The first ATP attempt successfully terminated 
46% of all monomorphic VTs, but accelerated the arrhythmia in 9.4%. Ten S-ICD patients 
experienced 13 electrical storms, versus 18 TV-ICD patients with 19 electrical storms. 
Patients with appropriate therapy had an almost two-fold increased relative risk of electrical 
storms in the TV-ICD group compared to the S-ICD group (P=0.05).  
Conclusions: In this trial, no difference was observed in shock efficacy of the S-ICD 
compared with the TV-ICD. Although patients in the S-ICD group were more likely to 
receive an ICD shock, the total number of appropriate shocks was not different between the 
two groups.  
Clinical Trial registration: URL: http://www.clinicaltrials.gov Unique identifier: 
NCT01296022 
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What is new?  
• This is the first trial to study the shock efficacy of the S-ICD and the TV-ICD in a 
randomized population.  
• Although efficacy of the first ATP attempt was 46% in monomorphic VTs, the 
number of shocks was not different between the S-ICD and the TV-ICD. 
 
 
What are the clinical implications?  
• Shock efficacy is not statistically different between the S-ICD and TV-ICD, and the 
decision for either device should be made in a shared decision-making process 
between patient and physician.  
• Physicians are recommended to observe the efficacy of ATP in the individual patient. 
When ATP is repeatedly unsuccessful in terminating ventricular arrhythmias, we 












Implantable cardioverter-defibrillators (ICDs) improve survival in those at risk for ventricular 
arrhythmias and sudden cardiac death1-3. The subcutaneous ICD (S-ICD) is an effective and 
extravascular alternative to the traditional transvenous ICDs (TV-ICD). The randomized 
controlled PRAETORIAN trial demonstrated non-inferiority of the S-ICD compared to the 
TV-ICD with regard to inappropriate shocks and complications in patients with a class I or IIa 
indication for ICD therapy according to current guidelines4. Antitachycardia pacing (ATP) 
has been developed as a painless method to terminate ventricular tachycardias (VT) and might 
decrease the number of appropriate shocks5. On the other hand, ATP might be given 
unnecessarily for VTs that would have ended spontaneously and might even accelerate VTs. 
The  reported efficacy ranges from 52-81%, and some studies have observed a higher 
mortality in patients treated by ATP6-10. Due to its extrathoracic design, the S-ICD is 
incapable of providing pacing therapy including ATP11,12. In this pre-specified secondary 
analysis of the PRAETORIAN trial, we aim to determine the efficacy and safety of ATP and 
shocks by comparing appropriate therapies in the S-ICD and TV-ICD. Specifically, we 
investigated whether ATP reduced the number of appropriate ICD shocks. 
 
Methods 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
Design and population of the PRAETORIAN trial 
The PRAETORIAN trial was an international, investigator-initiated, multicenter, randomized 
noninferiority trial that was conducted in the United States and Europe4. Enrollment started in 
March 2011 and ended in January 2017. Patients with a class I or IIa indication for ICD 










were eligible to participate in this trial. Patients with known VT at a rate below 170 beats per 
minute and patients with refractory recurrent monomorphic VT that could not be managed 
with medication or ablation therapy were excluded. Patients were randomly assigned in a 1:1 
ratio to receive either an S-ICD or TV-ICD, with stratification according to center. 
Programming of detection and therapy parameters was standardized and aimed to reduce 
avoidable appropriate and inappropriate shocks (Table 1). Deviation from the recommended 
device programming was allowed in order to fit the specific characteristics of the patient. The 
study protocol was approved by the institutional review committees and all the patients 
provided written informed consent. 
Endpoint definitions 
The main endpoints of this secondary analysis include total appropriate therapy and patients 
with appropriate therapy and first shock efficacy. A post hoc analysis was performed to 
evaluate the efficacy of ATP and the occurrence of electrical storms. Appropriate ICD therapy 
was defined as ATP or shock therapy for either VT or ventricular fibrillation (VF). Successful 
therapy was defined as either a shock or ATP that is able to convert the ventricular arrhythmia 
to sinus rhythm or atrial fibrillation within 5 seconds. Shock efficacy was defined as the 
percentage of successful shocks of the total amount of shocks. ATP efficacy was calculated as 
the proportion of successful ATP attempts of the total ATP delivered on a monomorphic VT. 
ATP for polymorphic VT and VF were excluded from the calculation of ATP efficacy, since 
ATP is not expected to be successful for these arrhythmias. The start of a ventricular 
arrhythmia marked the beginning of an episode and episodes end after conversion of the 
arrhythmia. Episodes were classified as discrete and storm episodes. An electrical storm was 
defined as three or more episodes of VT/VF within 24 hours13. Cardiac rhythm at time of ICD 
therapy was adjudicated by an independent Clinical Event Committee, consisting of three 










endpoints were performed in the modified intention-to-treat population, which included 
patients according to the group to which they had been randomly assigned, regardless of the 
device they received, but excluded patients who did not receive any ICD. An as-treated 
analysis that included patients according to the ICD that they first received, as well as a per 
protocol analysis that censors patients if they receive a different ICD at any moment in the 
study, were performed for the occurrence of electrical storms in both groups and are included 
in the Supplementary Appendix.  
Statistical analyses 
Descriptive statistics are reported as mean ± SD or median with interquartile range (IQR) for 
continuous variables and numbers and percentages for categorical variables. Baseline 
variables were compared using the fisher exact test, χ2 test, Student’s t-test or Mann–Whitney 
U-test when appropriate. For time to event variables, Kaplan-Meier curves displaying the 
pattern of events are constructed and 4-year Kaplan-Meier estimates of the event rate are 
reported for both study groups and compared using log-rank tests. Subjects without events are 
censored at their last known event-free time point. Hazard ratios (HR) and 95% confidence 
intervals (95%CI) were calculated by Cox proportional-hazards model. Univariable and 
multivariable Cox’ proportional hazard models were performed to find predictors of 
appropriate therapy. Relative risks (RR) and 95%CI were estimated using the Wald method. 
A negative binomial regression analysis was performed to assess the rate ratio of appropriate 
shocks between the groups. In order to adjust for multiple episodes per patient, shock and 
ATP efficacy estimations were adjusted using the generalized estimating equation (GEE) 
method with exchangeable correlation matrix. A P-value <0.05 was considered statistically 
significant. All statistical analyses were performed using R software version 4.0.3 (RStudio 
PBC, Boston, Massachussets). Detailed information on the statistical analyses can be found in 











In  the PRAETORIAN trial, a total of 849 patients were included of whom 426 patients were 
assigned to the S-ICD group and 423 patients to the TV-ICD group. Baseline characteristics 
of the population are presented in Table S1. Further details and results of the PRAETORIAN 
trial are published elsewhere4,14.  
In the S-ICD group, 86 patients had a total of 256 episodes with appropriate therapy, 
versus 78 patients in the TV-ICD group with 348 episodes, during a median follow-up time of 
52 months (IQR 41.4 – 68.5 months). There was no statistical difference in the number of 
patients with appropriate therapy between the two groups (48-month Kaplan–Meier estimated 
cumulative incidence, 19.4% and 17.5%, respectively; HR 1.12; 95%CI 0.83 – 1.53; P=0.45, 
Figure 1). Median time from start arrhythmia to first therapy was 17.4 seconds in the S-ICD 
group (IQR 15.0 – 20.4 seconds) versus 10.4 seconds in the TV-ICD group (IQR 9.2 – 12.6 
seconds).  
In the S-ICD group, of 2/256 episodes (0.8%) the electrograms of appropriate therapy 
were not available, versus 106/348 episodes (30.5%) with an unavailable electrogram in the 
TV-ICD group. Three patients who received appropriate therapy were primarily implanted 
with a different device than the group they were randomized to (0/86 in the S-ICD group 
versus 3/78 in the TV-ICD group). Five additional patients crossed over during follow-up 
(5/86 in the S-ICD group versus 0/78 in the TV-ICD group) and 13 patients received an 
upgrade to a CRT-D during follow-up (8/86 in the S-ICD group versus 5/78 in the TV-ICD 
group). A list of the crossovers is presented in Table S2. 
The clinical characteristics at baseline of patients with appropriate therapy were 
similar in the two groups (Table 2). Median age was 63 years (IQR 55 – 68), 17.1% were 
women, 68.3% had an ischemic cardiomyopathy and 28.1% received their ICD due to a 










multivariable analysis showed that a secondary prevention indication for ICD therapy and a 
lower left ventricular ejection fraction at baseline were significantly associated with an 
increased risk for appropriate therapy (P<0.01 and P<0.01, Table S3).  
Appropriate shocks  
In the S-ICD group, 83 patients were treated with at least one shock, versus 57 patients in the 
TV-ICD group (48-month Kaplan–Meier estimated cumulative incidence, 19.2% and 11.5%, 
respectively; HR 1.52, 95%CI 1.08 – 2.12, P=0.02, Figures 2 and 3). A total of 254 shocks 
occurred in 242 episodes in the S-ICD group and 228 shocks occurred in 193 episodes in the 
TV-ICD group (0.60 versus 0.54 shock per patient, Rate Ratio=1.11, P=0.68, Table S4). First 
and final shock efficacy were 93.8% and 97.9% in the S-ICD group versus 91.6% and 98.4% 
in the TV-ICD group (P=0.40 and P=0.70, Figure S1). The arrhythmias that were not 
terminated by the ICD all ended spontaneously after the final shock and no deaths were 
observed due to an inefficient shock. Shock efficacy adjusted per multiple episodes per 
patient is described in Table S5A. This analysis included 11 S-ICD patients who had 18 
shocks on VTs below the programmed therapy zone due to cardiac oversensing. Details of the 
number of shocks across different arrhythmia rates are provided in Table S6. Median time 
from start arrhythmia to first shock was shorter in the TV-ICD group (17.8 seconds in the S-
ICD group [IQR 15.3 – 20.6 seconds] versus 13.8 seconds in the TV-ICD group [IQR 11.6 – 
17.1 seconds]).  
Appropriate ATP 
As this analysis was performed on the modified intention-to-treat population, which included 
crossovers, 18 ATP attempts were observed in 5 patients in the S-ICD group. In the TV-ICD 
group, 328 ATP attempts occurred in 56 patients, of which 259 (79.0%) were first ATP 
attempts. Three of 86 patients (3.5%) in the S-ICD group and 21/78 patients (26.9%) in the 










were given on monomorphic VTs with an efficacy of 46% (95%CI 39.9% – 52.6%). The first 
ATP attempt on a monomorphic VT accelerated the tachycardia in 9.4% of all episodes, 
which affected 15 patients (19.2%, Figure 4). ATP efficacy decreased when multiple attempts 
were given (Table S5B). In total, 102/182 discrete episodes (56%) in the TV-ICD group were 
terminated by ATP only. Details of the efficacy of ATP across different arrhythmia rates are 
provided in Table S7.  
Electrical storms 
A total of 10/86 patients (11.6%) in the S-ICD group experienced 13 electrical storms, with 
89 storm episodes in which 91 shocks were administered by the ICD. In the TV-ICD group, 
18/78 patients (23.1%) experienced 19 electrical storms with 166 storm episodes in which 149 
shocks and 148 ATP attempts were delivered (Figure 5). Patients with appropriate therapy 
had an almost two-fold increased relative risk of electrical storms in the TV-ICD group 
compared to the S-ICD group (RR 1.98, 95%CI 0.98 –4.04, P=0.05). These findings were 
consistent in the as-treated (relative risk 1.99, 95%CI 1.02 – 4.04, P=0.04) and per protocol 
analyses (relative risk 1.99, 95%CI 0.98 – 4.04, P=0.05, Table S8). 
There were no significant differences in baseline characteristics of patients with an 
electrical storm compared with patients without an electrical storm (Table S9). In 6/19 
electrical storms (32%) in the TV-ICD group, more than one ATP attempt per episode was 
given and ICDs were programmed with more than the single ATP attempt that was specified 
in the protocol. The first ATP attempt successfully terminated the monomorphic VT in 54.6% 
of the discrete episodes, versus 35.9% in storm episodes (P<0.01). In the TV-ICD group, 
77/166 electrograms of storm episodes (46%) were overwritten due to limited storage 













In this secondary analysis of the randomized PRAETORIAN trial, we found no statistical 
difference in number of patients treated with appropriate ICD therapy in the S-ICD group and 
TV-ICD group. S-ICD patients were more likely to receive an appropriate shock, but the 
overall number of appropriate shocks was comparable between the two groups, despite the 
inability of the S-ICD to deliver ATP. We observed no difference in first and final shock 
efficacy in the two groups. ATP successfully terminated approximately half of the 
monomorphic VTs and one in four patients could be treated by ATP only. The efficacy of 
ATP decreased after the first attempt and the first ATP attempt accelerated the arrhythmia in 
9.4% of the episodes.  
The median time from start arrhythmia to first therapy and shock was shorter in the 
TV-ICD group compared to the S-ICD group, probably due to a combination of a shorter time 
to detection, the delivery of ATP and a shorter capacitor charge time of the TV-ICD. It is 
often postulated that a longer time to shock would result in a lower number of shocks, as it 
reduces the risk of needless treatment of unsustained ventricular arrhythmias. This was not 
confirmed by our results, as we showed a comparable number of shocks in the two groups.  
 ATP is recommended as preferred therapy for most ICD patients and has been 
considered a safe and painless alternative to defibrillation shocks8,15. Our results show that a 
number of monomorphic VTs in patients in the TV-ICD group could be terminated by ATP 
only, without affecting the overall number of appropriate shocks compared to patients in the 
S-ICD group. Simultaneously, there were more treated appropriate episodes in the TV-ICD 
group than in the S-ICD group, which may be the result of unnecessary treatment with ATP 
on ventricular arrhythmias that would otherwise have ended spontaneously. Although we 
observed that the first ATP attempt was successful in 46% of all episodes with a 











lower success rate, compared to previous studies6-8, can be explained by the patient selection 
in the PRAETORIAN trial, which excluded patients with VTs at a rate below 170 beats per 
minute or recurrent monomorphic VTs prior to implant. It has been indicated that VT 
acceleration by ATP might lead to electrical storms and a higher mortality 10. Whereas there 
was no difference in mortality in the PRAETORIAN trial4, patients with a TV-ICD had 
indeed a higher risk of electrical storms compared to patients with an S-ICD, despite the 
comparable baseline. In this study, ATP had a proarrhythmogenic effect in 9.4% of the 
episodes. In addition, we observed a significantly lower ATP efficacy in storm episodes, 
compared to discrete episodes. The higher incidence of electrical storms in the TV-ICD group 
could be associated with the capability of the TV-ICD to provide ATP, since 32% of the 
storms were given more than one ATP attempt per episode. Our data suggest that, in the 
studied population, ATP therapy should be limited to a single attempt to observe the efficacy 
in the individual patient. After a positive effect of ATP is demonstrated, ATP programming 
may be extended.  
This analysis has several limitations. First, patients with known VT at a rate below 170 
beats per minute and patients with refractory recurrent monomorphic VT that could not be 
managed with medication or ablation therapy were not eligible to participate in the 
PRAETORIAN trial. It is therefore unclear whether the results of this analysis apply to all 
ICD patients. Second, the majority of episodes with missing electrograms occurred in the TV-
ICD group, as this device often overwrites previously stored episodes to preserve storage 
capacity. These episodes could not be adjudicated and lead to an underestimation of the 
amount and nature of appropriate therapy in the TV-ICD group. Finally, the morphology of 
the electrograms of the TV-ICD does not resemble the surface electrocardiogram as much as 











ventricular and supraventricular arrhythmias, which could have influenced the classification 
of appropriate therapy in the TV-ICD group.  
 
Conclusions 
The results of this analysis show that the S-ICD is equally effective as the TV-ICD in 
terminating ventricular arrhythmias. The capability to provide ATP in the TV-ICD group led 
to fewer patients with appropriate shocks, but the total number of appropriate shocks was not 
different in the two study groups. ATP is less effective during storm episodes than during 
discrete episodes and ATP efficacy is mainly a result of the first attempt. In addition, ATP can 
accelerate arrhythmias and more electrical storms were observed in the TV-ICD group. In 
patients who are not expected to benefit from ATP, we suggest to limit ATP therapy to a 
single attempt.  
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Table 1. Standardized ICD programming in the PRAETORIAN trial.  







Fast VT zone VF zone 
Arrhythmia detection 
zones (beats/min) 
>180 >250 >167 >182 >250 
Time to initiate therapy 
(charge for shock or ATP) 
Fixed (18/24: 6 
seconds) 
Fixed (18/24: 4.3 
seconds) 
11 seconds 10 seconds 7.2 seconds 





No therapy (1) 1 burst of 
ATP* 






Pacing programming Postshock pacing “On”  VVI 40 beats/min 











Table 2. Patient characteristics of patients with appropriate therapy  





N = 86 N = 78 
 
Median age (IQR) 63 (55-68) 63 (54-68) 0.90 
Female ― no.(%) 11 (12.8) 17 (21.8) 0.13 
Diagnosis ― no.(%) 
  
0.91 
- Ischemic cardiomyopathy 58 (67.4) 54 (69.2) 
 
- Nonischemic cardiomyopathy 21 (24.4) 18 (23.1) 
 
- Genetic arrhythmia syndrome 4 (4.7) 4 (5.1) 
 
- Idiopathic VF 1 (1.2) 2 (2.6) 
 
- Congenital heart disease 1 (1.2) 0 (0.0) 
 
- Other 1 (1.2) 0 (0.0) 
 
Secondary prevention ― no.(%) 22 (25.6) 24 (30.8) 0.46 
Median ejection fraction (IQR) 28 (20-35) 29 (22-35) 0.55 
Mean QRS duration ±SD 107±19 108±19 0.83 
NYHA class ― no.(%) 
  
0.13 
- I 32/86 (37.2) 34/77(44.2) 
 
- II 38/86 (44.2) 37/77 (48.1) 
 
- III/IV 16/86 (18.6) 6/77 (7.8) 
 
Median body mass index (IQR)* 27.2 (24.4-30.1) 27.4 (25.0-30.5) 0.52 
Medication at discharge ― no.(%) 
   
- Beta blocker 68 (79.1) 67 (85.9)  0.25 
- Amiodarone 6 (7.0) 4 (5.1) 0.87 














Figure 1. Kaplan Meier curve of all patients with appropriate therapy in the 
PRAETORIAN trial 
 
Figure 2. Overview of all patients with appropriate therapy, appropriate episodes and 
therapies.  
 
Figure 3.  
A) Total number of patients with appropriate therapy. B) Total delivered therapy. 
Figure 3A: Patients can be represented in both discrete and storm episodes. 
 
Figure 4.  
A) Successful conversion to sinus rhythm after ATP. B) Acceleration of VT after ATP, 
ultimately terminated by a shock (shock not shown).  
 
Figure 5.  
Electrical storms in the S-ICD and TV-ICD. A) Number of shocks and ATP per episode 
per storm. B) Electrical storms with only shocks. Figure 5A: Each horizontal row 
represents one electrical storm. Therapies that accelerated the arrhythmia are shown with a 
dot above the therapy. Figure 5B: Each horizontal row represents one electrical storm. Only 
electrical storms with at least one shock are presented in this figure. There were 91 shocks in 
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due to first shock
9.4% acceleration 
due to first ATP
1.7% acceleration 






























S-ICD TV-ICD S-ICD TV-ICD S-ICD TV-ICD
Total Discrete episodes Storm episodes















S-ICD TV-ICD S-ICD TV-ICD S-ICD TV-ICD











































 http://ahajournals.org by on N
ovem
ber 29, 2021
